I-Retatrutide , umuthi wokuhlola owasungulwa ngu-Eli Lilly, uphinde waba yizihloko zezindaba ngemiphumela yawo kubantu abakhuluphele abanesifo sikashukela sohlobo lwesibili. Idatha ivela esivivinyweni somtholampilo sesigaba sesi-2 esishicilelwe kuyi- The Lancet futhi sethulwe engqungqutheleni yaminyaka yonke ye-European Association for the Study of Diabetes, ebibanjelwe eMilan.
Lolu cwaningo, olwenziwe ezikhungweni zezokwelapha nezibhedlela ezingu-92 emazweni ayisishiyagalombili , okuhlanganisa neSpain, luqinisa umqondo wokuthi le nhlanganisela ingaba yindlela yokwelapha yesiguli esivame ukungasabeli kahle ekwelashweni kokukhuluphala. Sibhekisela kubantu abadala abakhuluphele noma abakhuluphele abanesifo sikashukela sohlobo lwesibili , inhlanganisela evamile futhi okunzima ukuyiphatha.
Kuyini i-retatrutide futhi ihluke kanjani?
I-Retatrutide iyi- agonist ephindwe kathathu esebenza kuma-receptor e-GIP, GLP-1, kanye ne-glucagon hormone. Le nhlanganisela iyayihlukanisa neminye imithi yokwehlisa isisindo kanye nesifo sikashukela ehlose ama-receptor amabili noma amathathu kuphela. Abacwaningi bayayifundela ukukhuluphala, isifo sikashukela sohlobo 2, kanye nezinkinga ezihlobene nesisindo ezifana nesifo senhliziyo kanye ne-obstructive sleep apnea.
Indatshana yamazwe ngamazwe enendlela yokukhuluma yaseSpain
Lolu cwaningo, olubizwa ngokuthi i-TRIUMPH-2 , luwucwaningo lwesigaba III, olungahleliwe, olungaboni kabili, olulawulwa yi-placebo. Abantu abangu-2.047 bahlolwa, kanti abangu-1.152 banikezwa ngokungahleliwe ukuthola imijovo ye-placebo noma i-retatrutide kanye ngesonto ngemithamo engu- 4, 9, noma 12 milligrams . Bonke abahlanganyeli bathole nokwelulekwa ngokudla kanye neziqondiso mayelana nomsebenzi womzimba.
Ucwaningo lwenziwe amasonto angaphezu kwama-80 ezikhungweni zase-Argentina, e-Australia, eBrazil, e-India, eMexico, eRomania, eSpain nase-United States. Lolu cwaningo lwamazwe ngamazwe lusiza ukuqinisekisa ukuthi imiphumela imelela kakhulu, yize ababhali ngokwabo bekhomba ukuthi lokhu kuseyisidakamizwa socwaningo futhi akukatholakali emakhemisi.
Imiphumela ngesisindo somzimba
Esontweni lama-80, isilinganiso sokulahlekelwa isisindo sasingu -11,9% ngamamililitha angu-4 , 16,8% ngamamililitha angu-9, kanye no-18,8% ngamamililitha angu-12. Eqenjini le-placebo, isilinganiso sokulahlekelwa isisindo sasingu-5,1%. Ngokusho kwabacwaningi, lezi zibalo zimelela ukwehla okukhulu nokuqhubekayo kubantu abavame ukwehlisa isisindo kancane ngezinye izindlela zokwelapha.
Idatha iphinde ikhombise ukuthi abangaphezu kwengxenye yabahlanganyeli abasahlangabezani nemigomo yokukhuluphala, nokuthi cishe ukwehla okumaphakathi okungu-20% kufinyelelwe ngomthamo wama-milligram angu-12 kubantu abakhuluphele ngokweqile noma abakhuluphele abanesifo sikashukela sohlobo 2. Noma kunjalo, ochwepheshe bagcizelela ukuthi le miphumela kufanele ihunyushwe ngaphakathi kokuhlolwa kwezokwelapha nangaphansi kokuqondisa kwezokwelapha.
Ukuthuthuka kwengozi ye-glucose kanye ne-cardiometabolic
Ngokuphathelene nokulawulwa kwesifo sikashukela, i-glycated hemoglobin (A1c) yehle ngesilinganiso esingu- 1,38% ngamamililitha angu-4 , 1,50% ngamamililitha angu-9, kanye no-1,45% ngamamililitha angu-12. Eqenjini le-placebo, ukwehla kwaba ngu-0,45%. I-A1c ibonisa ukulawulwa kwe-glucose ezinyangeni ezimbili kuya kwezintathu ezedlule, ngakho-ke lo mehluko ubhekwa njengobalulekile ngokwezokwelapha.
Ukwelashwa kuhlotshaniswe nokuthuthuka kwezici eziyingozi ze-cardiometabolic, njengomfutho wegazi kanye namaphrofayili e-lipid , kanye nokwehla kweprotheni ye-C-reactive ezwela kakhulu, uphawu lokuvuvukala. Imiphumela emibi ebikwe kakhulu kwakuyi-gastrointestinal , okuyinto evamile kulolu hlobo lwemithi.
Okushiwo abacwaningi
UJuan P. FrÃas, umqondisi wezokwelapha kanye nomphenyi oyinhloko eMetabolic Research Institute eLos Angeles, uveza ukuthi iningi labantu abanesifo sikashukela sohlobo lwesibili nabo bakhuluphele ngokweqile, futhi ukwelapha zombili lezi zimo ngesikhathi esisodwa bekulokhu kuyinselele yezokwelapha . Esifundweni se-TRIUMPH-2, i-retatrutide yehlise kakhulu isisindo kanye namazinga kashukela egazini, futhi abantu abangafika ku-40% bafinyelele amazinga e-A1c ngaphakathi kwebanga elijwayelekile.
Elinye iphuzu eliqokonyiswe abacwaningi ukuthi umuthi ubonise umphumela ngisho nangesilinganiso esiphansi kakhulu esifundwe, ama-milligram angu-4 . Lokhu kungenza kube lula ukwelashwa komuntu siqu futhi kulungise kangcono ukuqina kwesiguli ngasinye, yize ukuphepha kwesikhathi eside nemiphumela yezokwelapha yangempela kusazodinga ukuhlaziywa.
Ukwelashwa okungakagunyazwa okwamanje
Kubalulekile ukukhumbula ukuthi i-retatrutide ayigunyaziwe kwezentengiselwano futhi isabhekwa njengomuthi ocwaningwayo . Akufanele ididaniswe nomkhiqizo osuvele uvunyelwe noma ithengwe ngeziteshi ezingalawulwa, njengoba kukhona isexwayiso sezempilo mayelana nemijovo yokwehlisa isisindo engagunyaziwe , njengoba kungekho siqinisekiso mayelana nokwakheka kwayo, ikhwalithi, noma ukuphepha. Iziphathimandla zezempilo zigcizelela ukuthi ukusetshenziswa kwayo kufanele kukhawulelwe ezivivinyweni zemitholampilo ezigunyaziwe.
Imiphumela yesilingo se-TRIUMPH-2 retatrutide njengenye yezindlela zokwelapha ezithembisayo kakhulu zokukhuluphala kubantu abanesifo sikashukela sohlobo lwesibili, ngokulahlekelwa isisindo okufika ku- 18,8% kanye nokuthuthuka okucacile emazingeni kashukela kanye nengozi ye-cardiometabolic. Kodwa-ke, kuseyisidakamizwa sokuhlola, esilinde ukuvunyelwa, futhi ikusasa laso lizoncika ekuhlolweni okwengeziwe kokusebenza kwayo kwesikhathi eside, ukubekezeleleka, kanye nokuphepha. Ukubamba iqhaza kweSpain kanye nokwethulwa kwayo eMilan kuqinisa intshisekelo yaseYurophu kule datha, okwamanje, okufanele ihunyushwe ngokucophelela nangokuqinile kwesayensi.